Evidence map›Paper›PMID 38127986›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells.

Ori Hassin, Miriam Sernik, Adi Seligman, Felix C E Vogel, Max D Wellenstein, Joachim Smollich, Coral Halperin, Anna Chiara Pirona, Liron Nomi Toledano, Carolina Dehesa Caballero and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 3 countries.

Ori Hassin *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Miriam Sernik *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Adi Seligman *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0009-0000-8176-3509
Felix C E VogelDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center, Heidelberg 69120, Germany.ORCID 0000-0003-4067-2074
Max D WellensteinDivision of Tumour Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
Joachim SmollichDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Coral HalperinDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.
Anna Chiara PironaDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Liron Nomi ToledanoDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Carolina Dehesa CaballeroDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center, Heidelberg 69120, Germany.
Lisa SchlickerDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center, Heidelberg 69120, Germany.
Tomer-Meir SalameMass Cytometry Unit, Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel.
Avital Sarusi PortuguezThe Mantoux Bioinformatics Institute of the Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot 7610001, Israel.
Yael AylonDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Ruth Scherz-ShouvalDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0002-4570-121X
Tamar GeigerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.
Karin E de VisserDivision of Tumour Biology and Immunology, Oncode Institute, Netherlands Cancer Institute, Amsterdam 1066CX, The Netherlands.
Almut SchulzeDivision of Tumor Metabolism and Microenvironment, German Cancer Research Center, Heidelberg 69120, Germany.
Moshe OrenDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-4311-7172
Weizmann Institute of Science · ILGerman Cancer Research Center · DEThe Netherlands Cancer Institute · NL

Funding

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) G-201906-00324German-Israeli cooperation in cancer research CA-209Robert Bosch Stiftung (RBS) 713690-01
6 · The paper itself

Abstract

The

Indexed as

Breast NeoplasmsTumor Suppressor Protein p53AdipocytesAdipose TissueFemaleGenes, p53HumansTumor MicroenvironmentTumor Suppressor Protein p53adipocytesbreast cancerp53preadipocytes

Identifiers

PMID38127986
PMCPMC10756271
OpenAlexW4390046327

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.